FDA Brief

Warning letters Drugs

FDA warning letter to

Bio-Medical Pharmaceutical Manufacturing Corporation

High riskIssued Feb 5Posted Feb 10Center for Drug Evaluation and Research (CDER)

Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.

What happened

FDA inspected the Houston facility from August 25 to 29, 2025, and found sterile OTC drug manufacturing without classified cleanrooms or ISO 5 conditions for aseptic filling, insanitary conditions, inadequate water/equipment controls, and missing process and cleaning validation. FDA also found missing release and sterility testing and, in its drug listing system, no listing for a “Solution” drug. After a November 4, 2025 teleconference, a customer suspended distribution and recalled all batches within expiry.

What FDA found

  1. Bio-Medical lacked written procedures and validated aseptic/sterilization processes to prevent microbial contamination of sterile drugs, and lacked classified cleanrooms or ISO 5 areas for aseptic filling.

    21 CFR 211.113(b) and 211.42(c)(10)
  2. It used inadequately designed and maintained equipment, including a water system with dead legs and stagnant water, and lacked adequate production and process control procedures.

    21 CFR 211.63 and 211.100(a)
  3. It failed to clean, maintain, and sanitize or sterilize equipment at appropriate intervals, and lacked cleaning validation for shared equipment.

    21 CFR 211.67(a)
  4. It released drug batches without appropriate identity and strength testing, microbial testing, or sterility testing for products purported to be sterile.

    21 CFR 211.165(a), 211.165(b), and 211.167(a)
  5. It failed to list a “Solution” drug with FDA as required.

    FD&C Act section 510(j), 21 U.S.C. 360(j); 21 CFR Part 207

What FDA wants

FDA tells Bio-Medical to correct the violations promptly and respond in writing within 15 working days with corrective action plans, risk assessments, validation and remediation plans, and to clarify whether it will keep making sterile drugs for the U.S. market. FDA also recommends a qualified CGMP consultant and a six-system audit.

Who should pay attention

  • brands or owners that use this contract manufacturer
  • distributors and retailers selling OTC sterile solutions
  • drug companies using shared equipment or similar water systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk